secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001682852-25-000031
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B
--------------------------------------------------------------------------------

- Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).
- Reiterates 2025 revenue guidance $1.5-2.5B; expects H1 revenue ~$0.2B due to seasonality.
- Announces cost-cutting plan: reduce GAAP operating costs by $1.4-1.7B by 2027; new 2027 estimate $4.7-5.0B.
- Pipeline milestones: next-gen COVID vaccine PDUFA May 31; RSV vaccine PDUFA June 12; flu/COVID combo approval targeted 2026.
- Cash and investments $8.4B at March 31 (down from $9.5B at Dec 31); expects year-end ~$6B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/0001682852-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/mrna-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001682852-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer